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Background: 
Adenosine has been shown to have a wide spectrum of unique pain-relieving effects in various clinical 
situations. The aim of this study was to investigate the effects of intraoperative adenosine infusion on acute 
opioid tolerance and opioid induced hyperalgesia induced by remifentanil in adult patients undergoing 
tonsillectomy.
Methods: 
For this study, ninety patients were randomly allocated into groups that receive either adenosine (adenosine 
group) or saline (remifentnail group) intravenously under remifentanil based anesthesia and saline (sevoflurane 
group) under sevoflurane anesthesia. The patients in adenosine group received adenosine at dose of 80 μg/kg/min, 
and those in remifentnail group and sevoflurane group received an equal volume of saline 10 minutes after 
the induction of anesthesia until the end of surgery. Intraoperative evaluation included time weighted mean 
remifentanil dose, and postoperative evaluations included degree of pain severity at 1, 6, 12, and 24 hours, 
time to first postoperative requirement, and analgesic dose required during 24 hours after operation.
Results: 
Time weighted mean remifentanil dose during intraoperative period in adenosine group was significantly 
lower than that of remifentnail group (P = 0.00). The first postoperative analgesic were required earlier in 
remifentanil group than sevoflurane group or adenosine group (P = 0.00). Pethidine requirement during 24 
hours in sevoflurane group and adenosine group was significantly lower than that of remifentnail group (P = 
0.00). The visual analog scale scores for pain in sevoflurane group and adenosine group were significantly lower 
than those of remifentnail group for 12 hours after operation (P = 0.00). Incidence of hypotension (P = 0.024) 
and number of ephedrine administered (P = 0.011) in adenosine group were significantly higher than those 
of sevoflurane group.
Conclusions: 
The above results suggest that intraoperative adenosine infusion prevent acute opioid tolerance and opioid 
induced hyperalgesia induced by remifentanil. (Korean  J  Pain  2011;  24:  7-12)
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INTRODUCTION
    Adenosine, one of purine compounds plays as sig-
nificant roles in central and peripheral nociception/prono-
ciception or antinociception/analgesia have been extensively 
reviewed [1-3]. Intraoperative adenosine infusion reduces 
inhalation anesthetic requirements and postoperative an-
algesic requirements in patients undergoing various surgi-
c a l  p r o c e d u r e s  [ 3 - 6 ] .  A l s o  a d e n o s i n e  i n f u s i o n  a t  a  
non-hypotensive low dose (80 μg/kg/min) during surgery 
reduced  the  inhalational  anesthetic  requirements  by 
20-50%  and  kept  intraoperative  systolic  blood  pressure 
levels more stable and less responsive to painful surgical 
stimuli in the adenosine group than in the placebo group. 
After  breast  surgery  and  hysterectomy,  postoperative 
opioid requirements during the first 24 h were reduced by 
27% and 18%, respectively, at a similar degree of pain re-
lief, suggesting an extended antinociceptive/analgesic ef-
fect of the adenosine treatment [4-6].
    Remifentanil is a short-acting opioid with predictable 
and rapid recovery that is relatively in dependent of the 
dose [7]. A corollary of short action is that patients may 
e x p e r i e n c e  c o n s i d e r a b l e  s u r g i c a l  p a i n  i n  t h e  i m m e d i a t e  
postoperative period. Supplemental opioids are thus often 
given prophyllactically to the patients who are likely to ex-
perience postoperative pain. Despite this precaution, post-
operative analgesic requirement in patients given intra-
operative remifentanil is often surprisingly great [8]. This 
observation suggests that remifentanil may be associated 
with opioid induced hyperalgesia (OIH).
    W e hypothesized that intraoperative remifentanil ad-
ministration  results  in  acute  OIH  that  is  manifested  by 
shortening of time of first postoperative analgesic require-
ment, increased postoperative pain and opioid requirement. 
We therefore tested whether intravenous adenosine admin-
istration  reduces  intraoperative  opioid  consumption  and 
opioid induced hyperalgesia.
MATERIALS  AND  METHODS
    After obtaining approval from the institutional review 
board and written informed consent, 90 ASA I-II adult pa-
tients undergoing elective tonsillectomy were enrolled in 
the study. Patients were excluded if they were less than 
18 years of age at the time of the surgery or underwent 
concurrent procedures at the time of tonsillectomy, includ-
ing patients with known obstructive sleep apnea who re-
quired m ultile v el surgery. P atien ts were ex cluded if the y 
had history of asthma, hepatic, renal and endocrine dis-
orders, coronary artery disease, and ingestion of methyl-
xanthine. Additional exclusionary criteria included patients 
who used illicit drugs, patients who had a known sensitivity 
to opiate or xanthine agonist or antagonist drugs (e.g. di-
pyridamole, aminophylline). 
    Patients were informed that they had equal chances 
of being randomly (sealed envelope method) assigned into 
three groups that receive either adenosine (adenosin group) 
or  saline  (remifentanil  group  and  sevoflurane  group) 
i n t r a v e n o u s l y .  T h e  p a t i e n t s  i n  a d e n o s i n e  g r o u p  r e c e i v e d 
adenosine  at  dose  of  80  μg/kg/min,  and  those  in  re-
mifentanil group and sevoflurane group received an equal 
volume of saline 10 minutes after the induction of anes-
thesia until the end of surgery. All patients were pre-
medicated with midazolam 2-3 mg and glycopyrrolate 0.2 
mg intramuscularly before arrival in the operating room. 
Routine  monitors  included  pulse  oximeter,  automated 
cuffed blood pressure, electrocardiogram, and end-tidal 
CO2.
    Induction of anesthesia was commenced with a slow 
(30-60 s) i.v. bolus dose of remifentanil 1 μg/kg and fol-
lo w ed b y pr opof o l 1 mg/kg in a d en osin e gr o u p and r e-
mifentanil group and with propofol 2 mg/kg in sevoflurane 
group and tracheal intubation was facilitated with rocuro-
nium 0.9 mg/kg in all groups. The anesthesia level was 
monitored using the BIS method. The BIS electrodes were 
placed on the forehead and connected to BIS monitoring 
system (BIS XP, A-2000, Aspect Medical Systems, USA). 
In adenosine group and remifentanil group, after intubation 
of trachea, end-tidal sovoflurane concentration was main-
tained at 1 minimum alveolar concentration (MAC), adjust 
to age. The patients in sevoflurane group received an equal 
volume and of saline in place of remifentanil, the concen-
tration of sevoflurane was titrated to maintain a bispectral 
index in the range 40 to 60. Remifentanil was started at 
a rate of 0.1 μg/kg/min and subsequently stepwise by 0.05 
μg/kg/min  increments  if  inadequate  analgesia  was 
suspected. Our criteria for possibly insufficient anesthesia 
were a heart rate that exceeded preinduction values by 15% 
and/or a systolic blood pressure that exceed baseline val-
ues by 20% at least 5 min. 
    If the mean arterial pressure decreased during the 
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Table 1. Demographic and Clinical Variance
Remifentanil group
(n = 30)
Sevoflurane group
(n = 30)
Adenosine group
(n = 30)
Age (yr)
Sex (M/F)
Weight (kg)
Operation time (min)
39.3 ± 9.7
18/12
64.5 ± 4.9
54.8 ± 5.0
40.1 ± 5.1
13/17
  65 ± 3.1
53.8 ± 5.0
37.1 ± 9.3
20/10
65.8 ± 5.2
54.0 ± 4.6
Data are presented as mean ± SD or numbers. Adenosine group: received adenosine and remifentanil intravenously, Remifentanil group:
received an equal volume of saline and remifentanil, Sevoflurane group: received an equal volume of saline under sevofne anesthesia. There
are no significant differences between groups.
duction of anesthesia, the patients received 10 mg i.v. bo-
lus doses of ephedrine. If the heart rate decreased to less 
t h a n  5 0  b e a t s / m i n ,  0 . 5  m g  i . v .  a t r o p i n e  b o l u s  w a s  
administered. At the end of surgery, neuromuscular block-
ade was reversed with neostigmine 0.05 mg/kg and atro-
pine 0.02 mg/kg w hen the train-of-f our ratio had r e-
turned to 25%. When BIS values reached 80 and sponta-
neous breathing was achieved, extubation was performed. 
R e m i f e n t a n i l  a n d  a d e n o s i n e  i n f u s i o n  w e r e  d i s c o n t i n u e d  
when the last surgical stitch was placed.
    Pain scores at swallowing saliva or other fluids were 
documented using the 10-point linear visual analog scale 
which is a straight line with the left end of the line repre-
senting no pain and the right end of the line representing 
the worst pain. Patients are asked to mark on the line 
where they think their pain is. Intraoperative evaluation in-
cluded time weighted mean remifentanil dose, and post-
operative evaluation included degree of pain severity at 30 
minute, and 6, 12, and 24 hours, the time to first post-
o p e r a t i v e a n a lges i c  (p e t h i d in e o r k e t o r o l a c )  r e q u ir e m e n t , 
and analgesic dose required during 24 hours. Side effects 
including postoperative hemorrhage, postoperative oxygen 
desaturation, readmission for pain, hypotension, brady-
c a r d i a  a n d  t r a n s i e n t  a t r i o v e n t r i c u l a r  b l o c k  w e r e  a l s o  
recorded. A trained anesthesiologist who was not involved 
in the study assessed pain, and analgesic consumption. An 
i.v. dose of pethidine 25 mg if patients reported V AS ≥ 
4 or i.v. dose of ketorolac 30 mg if V AS ＜ 4 were ad-
ministered during recovery. 
    On  the  basis  of  a  preliminary  investigation  that 
showed hypothesized means of time to first postoperative 
analgesic requirement in postoperative period in adenosine 
group,  sevoflurane  group  and  remifentanil  group  were 
36.12 minute, 40.22 minute and 45.32 minute respectively, 
and standard deviation of subjects was 9.12. Sample size 
of 27 patients per group is needed to demonstrate a sig-
nificant difference, with power of 80% and an α coefficient 
of 0.05.
    The results are presen ted as mean ± SD or the n um-
ber of patients. Comparisons of age, body weight, oper-
ation time, time weighted mean remifentanil dose, the time 
to first postoperative analgesic requirement, VAS scores 
for pain and administered analgesics were conducted using 
One-way  ANOVA  with  tukey’s  post-hoc  multiple  com-
parisons. Pearson Chi-Square test was used to analyze 
categorical data such as gender, hypotension, bradycardia 
and  postoperative  hemorrhage.  Fisher’s  exact  test  was 
used to analyze categorical data such as Transient first 
degree arioventricular block, postoperative oxygen desatu-
ration, prolonged hospitalization (at least 5 days), and re-
admission for pain control. P ＜ 0.05 was considered stat-
istically significant.
RESULTS
    The three groups were comparable with respect to 
age, gender distribution, weight, and operation time (Table 1). 
    Time weighted mean remifentanil dose during intra-
operative period in adenosine group was significantly lower 
than that of remifentnail group (P = 0.00). The first post-
operative  analgesic  were  required  earlier  in  remifentanil 
g r o u p  t h a n  s e v o f l u r a n e  g r o u p  o r  a d e n o s i n e  g r o u p  (P = 
0.00), but not significant between adenosine group and 
sevoflurane group. Pethidine but not ketorolac requirement 
during 24 hours in sevoflurane group and adenosine group 
was significantly lower than that of remifentnail group (P 
= 0.00) (Table 2). 
    The V AS scores f or pain in sevoflurane group and ad-10 Korean J Pain Vol. 24, No. 1, 2011
Table 2. The Assessment of Received Analgesics During Perioperative Perioid
Remifentanil group
 (n = 30)
Sevoflurane group
 (n = 30)
Adenosine group
 (n = 30)
Time weighted mean remifentanil dose 
 ( μg/kg/min)
Time to first postoperative analgesic 
 requirement (min)
Analgesic type received 
  Pethidine (mg)
  Ketorolac (mg)
0.30 ± 0.02
39.2 ± 7.0
†
47.1 ± 9.4
†
53.9 ± 7.1
0
63.3 ± 7.9
37.67 ± 6.5
54.1 ± 6.2
  0.14 ± 0.04*
66.1 ± 9.1
35.2 ± 4.3
52.8 ± 7.0
Data are presented as mean ± SD or numbers. Adenosine group: received adenosine and remifentanil intravenously, Remifentanil group: 
received an equal volume of saline and remifentanil, Sevoflurane group: received an equal volume of saline under sevofne anesthesia. 
*P  ＜ 0.05 compared with remifentanil group. 
†P  ＜ 0.05 compared with the other groups.
Table 3. Visual Analog Scale Scores for Pain
Remifentanil group
 (n = 30)
Sevoflurane group
 (n = 30)
Adenosine group
 (n = 30)
1 hour after operation
6 hours after operation
12 hours after operation
24 hours after operation
 6.8 ± 1.0*
 6.1 ± 0.9*
 5.0 ± 0.7*
2.5 ± 0.6
 6.2 ± 0.9
 5.2 ± 1.0
 4.2 ± 0.8
2.33 ± 0.5
6.0 ± 0.9
5.0 ± 0.9
4.1 ± 0.7
2.1 ± 0.6
Data are presented as mean ± SD or numbers. Adenosine group: received adenosine and remifentanil intravenously, Remifentanil group: 
received an equal volume of saline and remifentanil, Sevoflurane group: received an equal volume of saline under sevofne anesthesia. 
*P  ＜ 0.05 compared with the other groups. 
Table 4. Side Effects During Perioperative Period
Remifentanil group
 (n = 30)
Sevoflurane group
 (n = 30)
Adenosine group
 (n = 30)
Hypotension
Bradycardia
Transient first degree AVB
Ephedrine administered
Atropine
Postoperative hemorrhage
Postoperative oxygen desaturation
Prolonged hospitalization
Readmission for pain control
2 (6.7)
2 (6.7)
0 (0)
3 (10) 
2 (6.7)
1 (3.3)
0 (0)
1 (3.3)
1 (3.3)
0 (0)
0 (0)
0 (0)
0 (0)
0
2 (6.7)
0 (0)
2 (6.7)
1 (3.3)
6 (20)*
4 (13.3)
2 (6.7)
7 (23.3)*
4 (13.3)
1 (3.3)
2 (6.7)
0 (0)
0 (0)
Data are presented as numbers and percentage. Adenosine group: received adenosine and remifentanil intravenously, Remifentanil group:
received an equal volume of saline and remifentanil, Sevoflurane group: received an equal volume of saline under sevofne anesthesia. 
*P ＜ 0.05 compared with sevoflurane group. AVB: atrioventricular block.
enosine group were significantly lower than those of re-
mifentnail group for 12 hours after operation (P = 0.00) 
(Table 3). 
    Incidence of hypotension (P = 0.024) and number of 
ephedrine administered (P = 0.011) in adenosine group were 
significantly higher than those of sevoflurane group (Table 4).
DISCUSSION
    W e confirmed our hypothesis that intraoperative re-C Lee, et al / Adenosine and Opioid Tolerance and Hyperalgesia 11
mifentanil administration results in acute opioid tolerance 
and OIH that are manifested by earlier requirement of the 
first postoperative analgesic, increased postoperative pain 
and  opioid  requirement  in  remifentanil  group  compared 
with sevoflurane group. In the adenosine group, the find-
ings of the acute opioid tolerance and OIH such as the 
earlier requirement of the first postoperative analgesic, in-
creased postoperative pain and opioid requirement was re-
versed to the sevoflurane group.
    Adenosine can exert complex effects on pain trans-
mission,  with  prominent  actions  at  both  peripheral  and 
spinal sites in preclinical models. The nature of the modu-
lation of pain signaling depends very much upon the re-
ceptor subtype activated. In the periphery, adenosine A1 
receptor activation produces pain suppression, while ad-
enosine A2 and A3 receptor activation produces pain en-
hancement [1-3].
    By administering of adenosine com pounds during sur-
gery, significant and long lasting perioperative pain relief 
can be achieved via central A1 recep tor-mediated an ti-
nociceptive/analgesic actions as well as via peripheral A2a 
or A3 receptor-mediated anti-inflammatory actions. Thus, 
adenosine compounds have significant potential for allevi-
ating various types of pain [9,10].
    Previous clinical studies have demonstrated that ad-
enosine infusions reduce perioperative anesthetic require-
ments and the total amount of analgesics used during the 
postoperative  period  in  patients  undergoing  abdominal 
hysterectomy [4,6] and isoflurane requirements in patients 
in patients undergoing shoulder surgery with general an-
esthesia [5]. Adenosine infusion was consistently shown to 
reduce anesthetic requirements in animal investigation [11]. 
The method of drug administration appears to influence 
the analgesic properties of adenosine in patients who un-
d e r g o  s u r g i c a l  p r o c e d u r e s  w i t h  g e n e r a l  a n e s t h e s i a .  T h e 
anesthetic technique used during surgery may also affect 
the efficacy of adenosine [3]. 
    Intravenous/systemic adenosine may attenuate peri-
operative pain primarily through its anti-inflammatory ac-
tions mediated by peripheral adenosine A2a or A3 receptors 
[12,13]. Such an anti-inflammatory effect may reduce the 
ongoing stimulation of peripheral nociceptors by suppress-
ing inflammation following tissue damage [14,15]. This as-
sumption is supported by the result of a study showing that 
an anti-inflammatory drug, ibuprofen, but not a long-act-
ing selective A1-adenosine receptor agonist, SDZ WAG994, 
provided significant postoperative analgesia after third- 
molar surgery [16].
    OIH is most broadly defined as a state of nociceptive 
sensitization caused by exposure to opioids. OIH may rep-
resen t one of man y reasons f or declining le v els of an-
algesia  while  receiving  opioids  or  a  worsening  pain 
syndrome. Another manifestation might be the experience 
of excessive pain after an otherwise straightforward surgi-
cal procedure. OIH is seen in both humans and in animal 
m o d e l s i n t h e  se t t ings  o f v e ry  l o w - d o s e o p i o i d  a d m in-
istration, during maintenance dosing, and when doses are 
e x t r e m e l y  h i g h  [ 1 7 ] .  L o w - d o s e  O I H  e f f e c t  i s  m e d i a t e d  
through opioid receptors, however high-dose OIH does not 
seem to be mediated by opioid receptors [18]. NMDA re-
ceptors have been shown to play a key role in in a opioid 
induced hyperalgesia [19]. Adenosine A2a receptors inhibit 
the conductance of NMDA receptor [20]. In examining ef-
fects of adenosine on tolerance to and dependence upon 
morphine, somewhat variable results are reported. Thus, 
some adenosine analogs do not affect, while others de-
crease, tolerance and dependence. 
    Postoperative pain scores were also significantly lower 
during the postoperative period in patients who received 
adenosine with pronounced and sustained relief lasting up 
to 48 hours. In a previous study, adenosine-treated pa-
tients also required appreciably less opioid analgesics with 
a reduction of up to 71% in PACU, and up to 45% at 48 
hours [9]. In our study, patients in adenosine group who 
received intravenous adenosine showed low VAS scores for 
pain for 12 hours after operation. The effect of adenosine 
on postoperative pain in our study outlasted the duration 
of the infusion. It is therefore speculated that adenosine 
may affect neuronal mechanisms involved in central hy-
perexcitability [3,10,20] and that such an effect would per-
sist longer than the period of administration of the drug.
    Hypotension was the most common adverse event 
among side effects, and occurred in 20% of adenosine- 
treated patients versus 6.7% of patients in the remifentanil 
group.  This  result  suggested  drug-to-drug  interactions 
between adenosine, inhaled anesthetics and opioids may 
worsen the hemodynamic eff ects of adenosine. The in-
cidence  of  atrioventricular  block  was  very  low  in  each 
treatment group.
    W e conclude that adenosine appears to demonstrate 
opioid-sparing, and analgesic properties and may be used 
as an adjunct in the intraoperative periods. Although stud-12 Korean J Pain Vol. 24, No. 1, 2011
ies suggest that adenosine might be a useful adjunct an-
algesic in the perioperative period, more studies are re-
quired to confirm these findings. Furthermore, dose-find-
ing clinical studies are warranted to establish the optimal 
dose for achieving a balance between efficacy and side ef-
fects profile for adenosine use in the perioperative setting.
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